Abstract. Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disorder leading to kidney failure. Recent advancements in

Autosomal dominant polycystic kidney disease (ADPKD), primarily caused by mutations in the PKD1 or PKD2 gene, is among the most common hereditary kidney diseases worldwide and is associated with signi...

This video reviews a cross-sectional study comparing how artificial intelligence models like ChatGPT and Google Gemini align with nephrologists when answerin...

YouTube video by JMIR Publications

Data from a phase 1/2 study demonstrated that the anti-APRIL zigakibart reduced proteinuria and stabilized kidney function of patients with IgA nephropathy (IgAN) at 100 weeks.

Diabetic nephropathy (DN) is one of the most frequent and severe complications of #diabetes mellitus that requires early reduction for the individuals most at risk. Effective intervention and management of DN requires a patient's deep insight and helpful information. Patients require accurate information to obtain prevention advice about their kidney disease to make appropriate decisions; individuals may seek artificial intelligence (AI) as online sources instead of communicating with clinicians. Therefore, to evaluate ChatGPT and Google Bard's capabilities in providing accurate information regarding DN compared to nephrologists, we assessed their performance in answering questions related to DN. Our study revealed AI would not eliminate the need for open and detailed discussion with healthcare professionals regarding medical concerns and treatment plans, as they indicated inconsistencies in responses. Additionally, it is imperative to provide real-time health information updates to meet the needs of individuals with DN.

Topline data from an interim analysis of the fourth cohort of its Phase 1b Multiple-Ascending Dose (MAD) clinical trial showed continued mechanistic dose...

Faculty physicians and surgeons of the Division of Nephrology at Loma Linda University School of Medicine will host the Rare Kidney Disease Conference December 7-8, 2024.